Skip to content

Efficacy and safety of buccal administration of midazolam as premedication in dental treatment under general anesthesia in pediatric patients

A single-arm clinical study on the efficacy and safety of buccal mucosa administration of midazolam (Buccolam Oromucosal Solution) as a premedication for dental treatment under general anesthesia in pediatric patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031230610
Enrollment
45
Registered
2024-02-01
Start date
2024-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric patient undergoing dental treatment under general anesthesia

Interventions

Midazolam administered buccally as a premedication for dental treatment under general anesthesia

Sponsors

Ito Takaya
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients scheduled for dental treatment under general anesthesia 2) Patients who are at least 1 year old and less than 10 years old at the time of consent 3) Patients with ASA classification 1 4) Patients with Frankl behavior rating scale 1 or 2 (low cooperativeness for dental treatment) 5) Patients with Mallampati scale 1 or 2 (low risk of upper airway obstruction) 6) Brodsky tonsillar size scoring 0, 1 or 2 (no evidence of tonsillar hypertrophy) 7) Patients with parental consent for participation in the study. However, for patients aged 7 years and older, written consent based on an assent document should be obtained from the patient him/herself.

Exclusion criteria

Exclusion criteria: 1) Patients allergic to midazolam or with a history of hypotension with midazolam 2) Patients with psychiatric disorders 3) Patients with respiratory disease 4) Patients at risk of upper airway obstruction such as small jaw, adenoids, or enlarged palatine tonsils 5) Patients with cold symptoms within 2 weeks prior to the scheduled surgery 6) Patients who are taking cytochrome P4503A (CYP3A) inducers or inhibitors, and who will have difficulty with withdrawal of these drugs when participating in this study. 7) Patients with myasthenia gravis 8) Patients with acute angle-closure glaucoma 9) Other patients who are deemed inappropriate to participate in the study by the principal investigator (subinvestigator).

Design outcomes

Primary

MeasureTime frame
Percentage of patients with a Mask Acceptance Scale (4-point scale) of 1 or 2 at 20 minutes after buccal administration of midazolam

Secondary

MeasureTime frame
1) Percentage of patients with a Ramsay Sedation Score (6-point scale of sedation after midazolam buccal administration) of 2 to 6 at 20 minutes after midazolam administration. 2) Percentage of patients with a Parental Separation Anxiety Scale (4-point scale of calmness of the child) of 1 or 2 at 20 minutes after midazolam buccal administration.

Contacts

Public ContactTakaya Ito

Institute of Science Tokyo Hospital

titoanph@tmd.ac.jp+81-3-5803-5549

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026